Research programme: hepatitis C therapeutics - Celgene

Drug Profile

Research programme: hepatitis C therapeutics - Celgene

Alternative Names: AVL-181; AVL-192

Latest Information Update: 09 Mar 2012

Price : $50

At a glance

  • Originator Avila Therapeutics
  • Developer Celgene Corporation
  • Class Small molecules
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 07 Mar 2012 Avila Therapeutics has been acquired by Celgene Corporation
  • 02 Sep 2011 Preclinical development is ongoing in USA
  • 26 Aug 2010 Pharmacodynamics data from in vitro studies in Hepatitis C presented at the 240th American Chemical Society National Meeting (ACS-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top